Topic: combination therapy
Combining AZ's MCL1 inhibitor AZD5991 with existing MEK or BRAF inhibitors could kill melanoma cells more effectively, scientists found.
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.
Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.
Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.
Novartis showed the combination is better at improving lung function than an ICS alone, giving it a boost as it heads toward an approval decision.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.
Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.
X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.
Tocagen, perhaps inevitably, has seen its brain cancer test flop, leading to a review of its operations.
AstraZeneca’s AZD1775 extended median survival in pancreatic cancer when combined with chemo and radiation in a phase 1 trial.